"approves Neupro formulation indications" Channels RSS

17:44 EDT 22nd October 2014 | BioPortfolio

BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.

Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open http://www.bioportfolio.net/report/23346-biochannel-publish-content-on-products-technologies.html

Interested? Contact priority@bioportfolio.com

Showing "approves Neupro formulation indications" Channels, all 19

Relevant

Revascularization Modalities and Indications

Probably Relevant

Orphan Indications

Examples of Ophan Drug Indications include: Anaemia, sickle cell Cystic fibrosis (CF) Duchenne muscular dystrophy Glioma Graft vs host disease (GvHD) Hepatoma, liver cancer Hodgkin Lymphoma Leukaemia, acute lymphocytic (ALL) Leukaemia, acute my...

Hepatitis B Immune Globulin Cangene

HepaGam B® [Hepatitis B Immune Globulin (Human) Injection] contains purified antibodies specific for the hepatitis B surface antigen (HBsAg). * It is approved in Canada and the United States for two indications making it the only product of its kin...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear histones to accumulate in both tumor and normal tissues,...

Drug Delivery - news, views, blogs

Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  Drug delivery technologies are patent protected formulation technologies that modify drug release profile, absor...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commercially most successful single-target group of biologic th...

OxyContin

OxyContin, an narcotic analgesic produced by Purdue Pharma LP, nets $3m in sales annually, placing it 8th in the world for annual sales. OxyContin in the brand name for oxycodone, and is similar to morphine. Indications include control of moderate to s...

Possibly Relevant

Phosphodiesterase 4 PDE 4 Inhibitors

Phosphodiesterase 4 (PDE-4) inhibitors have attracted considerable interest as potential therapeutic agents for diseases including chronic obstructive pulmonary disease. PDE-4 inhibitors are known to reduce elevated cAMP concentrations in inflammatory cell...

Tissue Growth Factors BMP 2

The classical tissue factors typically are proteins used for tissue repair and growth stimulation. Among the approved products are the growth factors PDGF, IGF, EGF, BMP and FGF. One of the commercially most successful growth factors is BMP-2 from Medtroni...

p38 mitogen activated protein kinase MAPK Inhibitors

The next generation of p38 mitogen-activated protein kinase (MAPK) inhibitors has reached clinical proof-of-concept studies in phase II in a broad range of indications. While the previous generation of p38 MAPK inhibitors suffered from side effects such as...

Epithelial cell adhesion molecule EpCAM CD326

Epithelial cell adhesion molecule (EpCAM; CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression of EpCAM has ...

Bone morphogenetic protein rhBMP

Bone morphogenetic protein 2 (rhBMP-2) is approved by the Food and Drug Administration for anterior lumbar interbody fusion and for acute open tibial fractures; rhBMP-7, on the other hand, is approved for long bone defects and has received a humanitarian d...

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across the venous arterial thromboembolic (VAT) space: The ...

Immunocytokines

Although the human cytokines interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha are approved marketed for tumor therapy, their use is rather limited due to severe systemic side effects. Targeted delivery of the cytokine may be an approach to redu...

Vancomycin

Vancomycin is an antobiotic indicated for the treatment of serious, life-threatening infections by Gram-positive bacteria that are unresponsive to other less-toxic antibiotics. In particular, vancomycin should not be used to treat methicillin-sensitive S...

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bln). Rituximab was first approved in 1997 by the FDA for ...

Fibroblast Growth Factors FGFs

The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development. Quite a number of FGF-R agonists are in development or even marketed in a range of...

Varicella

Varicella zoster virus (VZV) is one of eight herpes viruses known to infect humans (and other vertebrates). Varicella-zoster virus is known by many names, including: chickenpox virus, varicella virus, zoster virus, and human herpes virus type 3 (HHV-3). ...

ImuXen

ImuXen® is a liposomal technology platform designed to improve the delivery and effectiveness of DNA, protein and polysaccharide vaccines. Proof of concept preclinical studies with a number of vaccines have shown that ImuXen® technology can hel...


Search BioPortfolio:
Loading
Advertisement
Advertisement

Channels Quicklinks